Please use this identifier to cite or link to this item: http://localhost:8080/xmlui/handle/123456789/9309
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHuang, Shiang-Fen-
dc.contributor.authorWu, Alice Ying-Jung-
dc.contributor.authorLee, Susan Shin-Jung-
dc.contributor.authorHuang, Yu-Shan-
dc.contributor.authorLee, Chun-Yuan-
dc.contributor.authorYang, Te-Liang-
dc.date.accessioned2024-12-19T03:41:40Z-
dc.date.available2024-12-19T03:41:40Z-
dc.date.issued2023-06-
dc.identifier.urihttp://localhost:8080/xmlui/handle/123456789/9309-
dc.description.abstractAbstract COVID-19-associated mold infection (CAMI) is defined as development of mold infections in COVID-19 patients. Co-pathogenesis of viral and fungal infections include the disruption of tissue barrier following SARS CoV-2 infection with the damage in the alveolar space, respiratory epithelium and endothelium injury and overwhelming inflammation and immune dysregulation during severe COVID-19. Other predisposing risk factors permissive to fungal infections during COVID-19 include the administration of immune modulators such as corticosteroids and IL-6 antagonist. COVID-19-associated pulmonary aspergillosis (CAPA) and COVID-19-associated mucormycosis (CAM) is increasingly reported during the COVID-19 pandemic. CAPA usually developed within the first month of COVID infection, and CAM frequently arose 10e15 days post diagnosis of COVID-19. Diagnosis is challenging and often indistinguishable during the cytokine storm in COVID-19, and several diagnostic criteria have been proposed. Development of CAPA and CAM is associated with a high mortality despiteappropriate anti-mold therapy. Both isavuconazole and amphotericin B can be used for treatment of CAPA and CAM; voriconazole is the primary agent for CAPA and posaconazole is an alternative for CAM. Aggressive surgery is recommended for CAM to improve patient survival. A high index of suspicion and timely and appropriate treatment is crucial to improve patient outcome.en_US
dc.language.isoen_USen_US
dc.publisherElsevier Taiwan LLCen_US
dc.subjectAspergillosisen_US
dc.subjectMucormycosisen_US
dc.subjectCOVID-19en_US
dc.subjectCAPAen_US
dc.subjectCAMen_US
dc.titleCOVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosisen_US
dc.typeArticleen_US
Appears in Collections:VOL 56 NO 3 2023

Files in This Item:
File Description SizeFormat 
442-454.pdf1.97 MBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.